1041641-72-8Relevant articles and documents
Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational in Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors
Shahbazi, Sajad,Kaur, Jagdeep,Kuanar, Ananya,Kar, Dattatreya,Singh, Shikha,Sobti, Ranbir Chander
, p. 342 - 351 (2017/11/20)
Alzheimer's disease (AD), a worldwide renowned progressive neurodegenerative disorder, is the most common cause of dementia. There are several studies on the important role of cholesterol metabolism in AD pathogenesis, which indicated that the high concen
Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
Park, William K.C.,Kennedy, Robert M.,Larsen, Scott D.,Miller, Steve,Roth, Bruce D.,Song, Yuntao,Steinbaugh, Bruce A.,Sun, Kevin,Tait, Bradley D.,Kowala, Mark C.,Trivedi, Bharat K.,Auerbach, Bruce,Askew, Valerie,Dillon, Lisa,Hanselman, Jeffrey C.,Lin, Zhiwu,Lu, Gina H.,Robertson, Andrew,Sekerke, Catherine
, p. 1151 - 1156 (2008/09/19)
4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Muenchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and C log P values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.
